BACKGROUND: Injection drug users (IDUs) are at high risk of hepatitis B (HBV) infection, and hepatitis B vaccination coverage in IDUs is low. Recent studies demonstrate that syringe exchange programs are effective venues to reach and immunize IDUs. The purpose of this paper was to determine if targeting IDUs for HBV vaccination through syringe exchange programs is economically desirable for the healthcare system and to assess the relative effectiveness of several different vaccination strategies. METHODS: Active IDUs in Chicago IL and Hartford and Bridgeport CT (N=1964) were recruited and screened through local syringe exchange programs, randomized to a standard (0, 1, 6 months) or accelerated (0, 1, 2 months) vaccination schedule, and followed from May 2003 to March 2006. Analyses were conducted in 2007. The vaccination program's costs were balanced against future HBV-associated medical costs. Benefits in terms of prevented acute HBV infections and quality-adjusted life years were estimated based on a Markov model. RESULTS: HBV vaccination campaigns targeting IDUs through syringe exchange programs are cost-saving. The most cost-saving strategies include giving the first dose to everyone at screening, administering the vaccination under the accelerated schedule (0, 1, 2 months), and obtaining highly discounted vaccine from local health departments. CONCLUSIONS: It is economically inappropriate to offer HBV screening in the absence of vaccination. Existing syringe exchange programs in the U.S. should include HBV vaccination.
RCT Entities:
BACKGROUND: Injection drug users (IDUs) are at high risk of hepatitis B (HBV) infection, and hepatitis B vaccination coverage in IDUs is low. Recent studies demonstrate that syringe exchange programs are effective venues to reach and immunize IDUs. The purpose of this paper was to determine if targeting IDUs for HBV vaccination through syringe exchange programs is economically desirable for the healthcare system and to assess the relative effectiveness of several different vaccination strategies. METHODS: Active IDUs in Chicago IL and Hartford and Bridgeport CT (N=1964) were recruited and screened through local syringe exchange programs, randomized to a standard (0, 1, 6 months) or accelerated (0, 1, 2 months) vaccination schedule, and followed from May 2003 to March 2006. Analyses were conducted in 2007. The vaccination program's costs were balanced against future HBV-associated medical costs. Benefits in terms of prevented acute HBV infections and quality-adjusted life years were estimated based on a Markov model. RESULTS:HBV vaccination campaigns targeting IDUs through syringe exchange programs are cost-saving. The most cost-saving strategies include giving the first dose to everyone at screening, administering the vaccination under the accelerated schedule (0, 1, 2 months), and obtaining highly discounted vaccine from local health departments. CONCLUSIONS: It is economically inappropriate to offer HBV screening in the absence of vaccination. Existing syringe exchange programs in the U.S. should include HBV vaccination.
Authors: D C Des Jarlais; D G Fisher; J C Newman; B N Trubatch; M Yancovitz; D Paone; D Perlman Journal: Am J Public Health Date: 2001-11 Impact factor: 9.308
Authors: Y Kato; K Nakata; K Omagari; Y Kusumoto; I Mori; R Furukawa; H Tanioka; H Tajima; M Yano; K Eguchi Journal: Intern Med Date: 2001-01 Impact factor: 1.271
Authors: Eric E Mast; Cindy M Weinbaum; Anthony E Fiore; Miriam J Alter; Beth P Bell; Lyn Finelli; Lance E Rodewald; John M Douglas; Robert S Janssen; John W Ward Journal: MMWR Recomm Rep Date: 2006-12-08
Authors: Andrew J Leidner; Neil Murthy; Harrell W Chesson; Matthew Biggerstaff; Charles Stoecker; Aaron M Harris; Anna Acosta; Kathleen Dooling; Carolyn B Bridges Journal: Vaccine Date: 2018-12-04 Impact factor: 3.641
Authors: Harinder S Chahal; Marion G Peters; Aaron M Harris; Devon McCabe; Paul Volberding; James G Kahn Journal: Open Forum Infect Dis Date: 2018-12-26 Impact factor: 3.835
Authors: Fabio Lugoboni; Raimondo Maria Pavarin; Chiara Resentera; Daniele Gambini Journal: Int J Environ Res Public Health Date: 2015-04-13 Impact factor: 3.390
Authors: Fabio Lugoboni; Gianluca Quaglio; Paolo Civitelli; Paolo Mezzelani Journal: Int J Environ Res Public Health Date: 2009-01-22 Impact factor: 3.390
Authors: Jack Stone; Natasha K Martin; Matthew Hickman; Margaret Hellard; Nick Scott; Emma McBryde; Heidi Drummer; Peter Vickerman Journal: PLoS One Date: 2016-05-25 Impact factor: 3.240